Jennifer Thorne, MD
Ophthalmology · Baltimore, MDNPI 1225063035
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $125,682 of the $128,269 with a category attached, or 98.0%. Gilead accounts for 76.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $62,975 and has fallen 85.5% since, to $9,162 in 2025. Among ophthalmology clinicians in MD with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 71 payments — averaging $1806.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$98K
- AbbVie$8K
- Merck$8K
- Genentech USA, Inc.$6K
- Sanofi US Services Inc.$3K
- Biocryst Pharmaceuticals, Inc.$3K
- plus $2K from 2 others
Across 1 payment — averaging $72,110 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$72K
What the payments were for
- Consulting fees$125,68298%
- Travel & lodging$2,1872%
- Food & beverage$4000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 49 | $98,000 |
| AbbVie | 3 | $8,100 |
| Merck | 9 | $8,018 |
| Genentech USA, Inc. | 6 | $6,177 |
| Sanofi US Services Inc. | 1 | $3,087 |
| Biocryst Pharmaceuticals, Inc. | 1 | $2,985 |
| F. Hoffmann-la Roche AG | 1 | $1,850 |
| Alcon | 1 | $52 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Humira$2,400
How this compares
$128,269 in reported general payments places this provider in the 95th percentile of 493 ophthalmology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Mycophenolate Mofetil | 38 | $3,434 |
| Prednisolone Acetate | 17 | $934 |
| Prednisone | 35 | $499 |
| ValacyclovirValacyclovir Hcl | 12 | $288 |
| ErythromycinErythromycin Base | 24 | $210 |
| Latanoprost | 20 | $142 |
| Timolol Maleate | 11 | $134 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Baltimore
- Alfred SommerBaltimore$2.9M
- Richard AdlerBaltimore$2.7M
- Peter McDonnellBaltimore$1.4M
- Esen AkpekBaltimore$782K
- Neil BresslerBaltimore$265K
- Adrienne ScottBaltimore$170K
- Earl CravenBaltimore$120K
- Peter CampochiaroBaltimore$103K
- Gail SchwartzBaltimore$85K
- John GottschBaltimore$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.